IgE is the least abundant Ig isotype, yet it plays a critical role in allergic reactions and host protection from helminth infection. Although IgE was discovered 50 years ago, the ultimate evidence for its role in human allergic diseases was obtained by the efficacy of anti-IgE therapy in many clinical trials on asthma and other allergic diseases. Beginning from the discovery of IgE 50 y ago, followed by studies of IgE receptors and activation mechanisms, this review provides a historic perspective of allergy research that has led to the development of anti-IgE therapy and other strategies targeting IgE and its receptors. Current IgE studies toward future precision medicine are also reviewed.
This work was supported by National Institutes of Health Grants HL124283, AR064418, and AI115534 (to T.K.) and by funding from the Nipponham Foundation for the Future of Food (to T.K.).
Abbreviations used in this article:
- histamine-releasing factor
- Received August 24, 2016.
- Accepted October 3, 2016.
- Copyright © 2016 by The American Association of Immunologists, Inc.